Abcam completes $340m strategic acquisition and expands kit capacity and capability
Cambridge, England (ots/PRNewswire) - - Completing $340m strategic acquisition of BioVision
- Expanding facilities in Eugene, further growing kits and assays portfolio
- Supporting the growing demand of the sector and accelerating execution of strategic plan
Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of BioVision and the expansion of its immunoassay capacity in Eugene, OR.
Across the life sciences sector, the!-->…